Stealth Liposomes and Sirna for the Treatment of Respitory Viral Infections

Grant number: 1047635 | Funding period: 2013 - 2015

Completed

Abstract

Respiratory infections caused by Influenza and Respiratory syncytial virus cause significant hospitalisations and deaths within the community. For example, RSV causes around 1000 hospital admissions of young children a year and there is no cure or vaccination. Therapies are limited and toxic. We will develop and test a novel therapy based on gene silencing to specifically target viral genes, and combine this with our novel drug delivery system for better treatment of these diseases.

Related publications (2)

Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection

A Supramaniam, Y Tayyar, DTW Clarke, G Kelly, D Acharya, KV Morris, NAJ McMillan, A Idris

2023-06-01

RNA interference (RNAi) is an emerging and promising therapy for a wide range of respiratory viral infections. This highly specifi..

Pattern recognition receptor immunomodulation of innate immunity as a strategy to limit the impact of influenza virus

A Pizzolla, JM Smith, AG Brooks, PC Reading

2017-04-01

Influenza remains a major global health issue and the effectiveness of current vaccines and antiviral drugs is limited by the cont..

University of Melbourne Researchers

Patrick Reading